Clinical Trials on Respiratory Virus Infections in Australia

Total 3347 results

Cynata Therapeutics Limited
Cerebral Palsy Alliance

Completed

The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause (MEND)

Covid19 | Acute Respiratory Distress Syndrome

Australia
Andrew Steer
National Health and Medical Research Council, Australia; Queen Fabiola Children... and other collaborators

Completed

Controlled Human Infection for Vaccination Against Streptococcus Pyogenes (CHIVAS)

Bacterial Infections | Gram-Positive Bacterial Infections | Strep Throat | Streptococcus Pharyngitis | Streptococcus Pyogenes Pharyngitis | Streptococcus Pyogenes Infection | Group A Streptococcus: B Hemolytic Pharyngitis | Group A Streptococcal Infection

Australia
Yangshengtang Co., Ltd
Syneos Health

Completed

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects

Chronic Hepatitis B

Australia
Gilead Sciences

Approved for marketing

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

SARS-CoV2 Infection

United States, Israel, Belgium, Spain, Australia, Denmark, Italy, Germany, France, Portugal, United Kingdom, Poland, Switzerland, Canada, Austria, Cyprus, Czechia, Estonia, Greece, Hungary, Iceland, Ireland, Lithuania, Netherlands, Romania and more
Novavax
Bill and Melinda Gates Foundation

Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Respiratory Syncytial Virus Infections

United States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Hepatitis C Virus Infection

France, Austria, Germany, Italy
Medical University Innsbruck
Queen's University, Belfast; Cystic Fibrosis Foundation; European Cystic Fibrosis...

Active, not recruiting

COVID-19 Antibody Responses In Cystic Fibrosis: CAR-CF

Covid19 | Cystic Fibrosis

Austria
Bayside Health
Monash University; Bupa Aged Care Australia

Recruiting

Nurse-led Antimicrobial Stewardship Intervention to Increase Antibiotic Appropriateness in Residential Aged Care Facilities

Respiratory Tract Infections | Urinary Tract Infections | Antimicrobial Stewardship | Skin and Soft Tissue Infections

Australia
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Atea Pharmaceuticals, Inc.

Completed

Study of AT-752 in Healthy Subjects

Dengue

Australia
Kirby Institute

Completed

Hepatitis B Acceptability and Vaccination Incentive Trial (HAVIT)

Hepatitis B

Australia
Medical University of Vienna

Completed

The Glycocalyx in COVID-19 Patients. A Pilot Study (Glycovid-19)

COVID-19 | Coagulation Disorder | Endothelial Dysfunction

Austria
GlaxoSmithKline

Completed

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

Influenza, Human

United States, Spain, France, Australia, South Africa, United Kingdom, Thailand, Hong Kong, Canada, Russian Federation, Japan, Norway, Brazil
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
AlloVir

Terminated

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant (Prevent)

BK Virus Infection | Epstein-Barr Virus Infections | Cytomegalovirus Infections | Adenovirus Infection | JC Virus Infection | Human Herpes Virus-6 Infection

Korea, Republic of, United States, Spain, France, Turkey, Australia, United Kingdom, Italy, Canada, Belgium
Arrowhead Pharmaceuticals

Withdrawn

Study of ARC-520 in Patient With Chronic Hepatitis B Virus

Chronic Hepatitis B

Australia
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Terminated

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Australia, New Zealand
Beyond Air Inc.

Unknown

A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients

Cystic Fibrosis | Mycobacterium Avium Complex | Non-Tuberculous Mycobacterial Pneumonia | Mycobacterial Pneumonia | Mycobacterium Abscessus Infection

Australia
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Sanofi

Completed

Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)

Japanese Encephalitis | Yellow Fever

Australia
Alexander Zoufaly
BioMérieux

Recruiting

Effect of IN Hospital PCR Based Assessment of Patients With Lower Respiratory Tract Infections on LEngth of Stay (INHALE)

Respiratory Infection

Austria
Sanofi

Completed

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Australia
Macfarlane Burnet Institute for Medical Research...
Department of Health and Human Services

Recruiting

Link Hepatitis C Notifications to Treatment in Tasmania

Hepatitis C

Australia
Kirby Institute
Janssen-Cilag Ltd.

Completed

DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) (DARE-C)

Hepatitis C, Chronic

Australia
Abbott

Completed

Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

Severe Respiratory Syncytial Virus Infection

Austria, Belgium, France, Germany, Italy, Norway, Poland, Slovenia, Spain, United Kingdom
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza

Australia, New Zealand, Philippines, South Africa
Macfarlane Burnet Institute for Medical Research...
The University of Queensland; Cairns Hinterland Health Hospital and Health...

Completed

Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%

Hepatitis C

Australia
International Antiviral Therapy Evaluation Center
Boehringer Ingelheim

Completed

2NN & CHARM Long-Term Follow-up Study

HIV Infections

Australia
Huahui Health

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Hepatitis B

Australia
FixHepC

Unknown

Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods (REDEMPTION)

Hepatitis C

Australia
St Vincent's Hospital Melbourne
National Health and Medical Research Council, Australia

Unknown

Determinants of Virological Response After Discontinuation of Nucleoside Analogue Therapy in Hepatitis B Patients (STOP)

Chronic Hepatitis B.

Australia
Kirby Institute

Withdrawn

Evaluation of Novel Point of Care Hepatitis B Diagnostic Assays

Hepatitis B

Australia
Kirby Institute

Recruiting

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

Hepatitis C

Australia
Macfarlane Burnet Institute for Medical Research...

Recruiting

Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)

Hepatitis C

Australia
Gilead Sciences

Completed

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

Respiratory Syncytial Virus

Korea, Republic of, Taiwan, Israel, United States, France, Singapore, Sweden, Australia, Canada, United Kingdom, Brazil, Germany, Netherlands, Spain, Switzerland
Gilead Sciences

Completed

CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study (CHARM)

Chronic Hepatitis B

Australia
Stichting European Myeloma Network
Fondazione EMN Italy Onlus

Completed

COVID-19 Infection and Multiple Myeloma (EMN-COVID)

Covid19 | Multiple Myeloma | Corona Virus Infection

Czechia, Netherlands, United Kingdom, Belgium, Germany, Austria, Greece, Italy
Merck Sharp & Dohme LLC

Terminated

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

Coronavirus Disease (COVID-19)

United States, Austria, Belgium
The George Institute

Completed

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY)

COVID-19 | Coronavirus Disease 2019

Australia, India
Kirby Institute
The University of New South Wales

Completed

Australian Trial in Acute Hepatitis C Recall Study (ATAHC Recall)

Acute Hepatitis C

Australia
GlaxoSmithKline

Completed

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

Respiratory Syncytial Virus Infections

United States, Spain, Canada, Finland, Panama, South Africa, New Zealand, Australia, France
Berlin Cures GmbH

Active, not recruiting

To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID (BLOC)

Long Covid

Germany, Austria, Finland, Spain, Switzerland
Arrowhead Pharmaceuticals

Completed

Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

Hepatitis B

Australia, Hong Kong, New Zealand
GlaxoSmithKline

Completed

Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared

Hepatitis B | Hepatitis A

Australia, Belgium, Spain
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

United States, Canada, Japan, Germany, Australia, South Africa
Bristol-Myers Squibb

Withdrawn

Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients

Chronic Hepatitis C

Australia
BioCryst Pharmaceuticals

Completed

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

Influenza

United States, Australia, Canada, Hong Kong, New Zealand, Singapore, South Africa
Melbourne Health

Completed

The Effect of Prophylactic Probiotic Lactobacilli in Enteral Feeding on Nosocomial Pneumonia Rates in Critically Ill Patients

Critical Illness

Australia
Murdoch Childrens Research Institute
Royal Children's Hospital; Mercy Hospital for Women, Australia

Completed

A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study (ELVIS)

Innate Immune Response

Australia
GlaxoSmithKline

Completed

Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine

Hepatitis B | Hepatitis A

Australia

Clinical Trials on Respiratory Virus Infections in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations